<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>[REDACTED] Progress Note</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Assessment</a></li><li><a href="#id2">Allergies and Adverse Reactions</a></li><li><a href="#id3">Plan</a></li><li><a href="#id4">Reason for Visit</a></li><li><a href="#id5">Encounters</a></li><li><a href="#id6">Immunizations</a></li><li><a href="#id7">Diagnostic Results</a></li><li><a href="#id8">Medications</a></li><li><a href="#id9">Problems</a></li><li><a href="#id10">Vital Signs</a></li><li><a href="#id11">Notes Section</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Assessment</a></h3><div>See Clinical Notes section</div><h3><a name="id2" href="#toc">Allergies and Adverse Reactions</a></h3><div><table>
    <thead>
        <tr>
                            <th>Medication/Group Name</th>
                <th>Reaction</th>
                <th>Severity</th>
                <th>Date</th>
        </tr>
    </thead>
    <tbody>
                <tr ID="AlertOBS-1000">
                    <td colspan="4">No known allergies</td>
                </tr>
    </tbody>
</table>
</div><h3><a name="id3" href="#toc">Plan</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="CarePlanRef-1001">
						<td>[REDACTED]</td>
						<td>APPOINTMENT</td>
						<td>FOLLOW UP</td>
				</tr>
				<tr ID="CarePlanRef-1002">
						<td>[REDACTED]</td>
						<td>APPOINTMENT</td>
						<td>TELEPHONIC F/U</td>
				</tr>
				<tr ID="CarePlanRef-1003">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CA 15-3</td>
				</tr>
				<tr ID="CarePlanRef-1004">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>LDH</td>
				</tr>
				<tr ID="CarePlanRef-1005">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>U/S breast, right</td>
				</tr>
				<tr ID="CarePlanRef-1006">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CEA</td>
				</tr>
				<tr ID="CarePlanRef-1007">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CBC With Diff and Plt</td>
				</tr>
				<tr ID="CarePlanRef-1008">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CMP</td>
				</tr>
				<tr ID="CarePlanRef-1009">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CA 125</td>
				</tr>
				<tr ID="CarePlanRef-1010">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>LDH</td>
				</tr>
				<tr ID="CarePlanRef-1011">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CEA</td>
				</tr>
				<tr ID="CarePlanRef-1012">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CBC With Diff and Plt</td>
				</tr>
				<tr ID="CarePlanRef-1013">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CMP</td>
				</tr>
				<tr ID="CarePlanRef-1014">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CA 125</td>
				</tr>
				<tr ID="CarePlanRef-1015">
						<td>[REDACTED]</td>
						<td>LABORDER</td>
						<td>CA 15-3</td>
				</tr>
	</tbody>
</table>
</div><h3><a name="id4" href="#toc">Reason for Visit</a></h3><div>FOLLOW UP</div><h3><a name="id5" href="#toc">Encounters</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="EncounterDiagnosisRef-1016">
							<td>[REDACTED]</td>
							<td>Uterine cancer</td>						
					</tr>
	</tbody>
</table>
</div><h3><a name="id6" href="#toc">Immunizations</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Instructions</th>
				<th>Refusal Reason</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
				<tr><td colspan="7">No data for this encounter</td></tr>
	</tbody>
</table>
</div><h3><a name="id7" href="#toc">Diagnostic Results</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Test</th>
				<th>Units</th>
				<th>Lower Limit</th>
				<th>Upper Limit</th>
				<th>Result</th>
				<th>Flag</th>
				<th>Comments</th>
				<th>Status</th>
				<th>Ordered By</th>
				<th>Specimen Source</th>
				<th>Lab Address</th>
		</tr>
	</thead>
	<tbody>
			<tr><td colspan="13">NONE</td></tr>
	</tbody>
</table>
</div><h3><a name="id8" href="#toc">Medications</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Name</th>
				<th>Route</th>
				<th>Dose</th>
				<th>Frequency</th>
				<th>Instructions</th>
				<th>Start Date</th>
				<th>End Date</th>
				<th>Status</th>
		</tr>
	</thead>
	<tbody>
					<tr ID="MedicationOBS-1017">
							<td/>
							<td>Atorvastatin Oral </td>
							<td>orally</td>
							<td>20.0 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1018">
							<td/>
							<td>Aspirin Oral </td>
							<td>orally</td>
							<td>1.0 capsule</td>
							<td>daily</td>
							<td> quantity sufficient for 30 days; 2 refills</td>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1019">
							<td/>
							<td>Amlodipine Oral </td>
							<td>orally</td>
							<td>5.0 mg</td>
							<td>daily</td>
							<td/>
							<td/>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1020">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1021">
							<td>[REDACTED]</td>
							<td>letrozole 2.5 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1022">
							<td>[REDACTED]</td>
							<td>letrozole 2.5 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1023">
							<td>[REDACTED]</td>
							<td>letrozole 2.5 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>daily</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1024">
							<td>[REDACTED]</td>
							<td>alendronic acid 70 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every week</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1025">
							<td>[REDACTED]</td>
							<td>calcium carbonate 648 MG Oral Tablet </td>
							<td>orally</td>
							<td>500.0 mg</td>
							<td>2 times per day</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
					<tr ID="MedicationOBS-1026">
							<td>[REDACTED]</td>
							<td>carboplatin 10 MG/ML Injectable Solution </td>
							<td>intravenously</td>
							<td>390.0 mg</td>
							<td>once</td>
							<td>Mix in D5W or NS.
Carboplatin is an irritant.</td>
							<td>[REDACTED]</td>
							<td>[REDACTED]</td>
							<td>on hold</td>
					</tr>
					<tr ID="MedicationOBS-1027">
							<td>[REDACTED]</td>
							<td>ondansetron 8 MG Oral Tablet </td>
							<td>orally</td>
							<td>1.0 tablet</td>
							<td>every 8 hours</td>
							<td/>
							<td>[REDACTED]</td>
							<td/>
							<td>active</td>
					</tr>
	</tbody>
</table>
</div><h3><a name="id9" href="#toc">Problems</a></h3><div><table>
	<thead>
		<tr>
							<th>Diagnosis</th>
				<th>Status</th>
				<th>Date of Diagnosis</th>
		</tr>
	</thead>
	<tbody>
				<tr ID="ProblemOBS-1028">
						<td>Cancer, female breast, left breast</td>
						<td>Active</td>
						<td/>
				</tr>
				<tr ID="ProblemOBS-1029">
						<td>Uterine cancer</td>
						<td>Active</td>
						<td/>
				</tr>
	</tbody>
</table>
</div><h3><a name="id10" href="#toc">Vital Signs</a></h3><div><table>
	<thead>
		<tr>
							<th>Date</th>
				<th>Type</th>
				<th>Value</th>
		</tr>
	</thead>
	<tbody>
			<tr><td colspan="3">NONE</td></tr>
	</tbody>
</table>
</div><h3><a name="id11" href="#toc">Notes Section</a></h3><div>	<ul><li>
		        Follow-Up: 
		        <p>
		        		

<br/>[REDACTED][REDACTED]<br/>
[REDACTED]

<br/>
<br/>Phone: [REDACTED] Fax: [REDACTED]


<br/>


<br/>Patient Name:Â [REDACTED]

<br/>Date of Birth:Â [REDACTED]

<br/>Medical Record #:Â [REDACTED]

<br/>Attending Physician:Â [REDACTED] (Hematology/Oncology)

<br/>Location:Â [REDACTED]

<br/>Referring Physician:Â [REDACTED], M.D. (Gynecological/Oncology)

<br/>


<br/>Follow-Up

<br/>Date of Visit:Â [REDACTED]

<br/>


<br/>History of Present Illness

<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
[REDACTED] female with history of HTN, HLD who is newly diagnosed with endometrial adenocarcinoma. She noticed blood in urine starting in 3/2022, however did not seek medical evaluation until 9/2022. She was evaluated by her gynecologist on [REDACTED], underwent endometrial curettage. Endocervical curettage did not reveal any malignancy but the endometrial curettage showed endometrial adenocarcinoma. She subsequently underwent laparoscopicÂ  TAH + BSO, bilateral pelvic and aortic nodal dissection and omentectomy by Dr. [REDACTED] on [REDACTED]. The post-surgical pathology showed endometrial adenocarcinoma, endometroid type, FIGO grade 3, measuring 4 cm, areas suspicious for lymph vascular invasion,Â myometrial invasion present well beyond 50%, 1/1 left pelvic node with tumor involvement with nodal extension with the greatest tumor deposit of 1.6 cm, 0/4 right pelvic nodes, 0/3 left aortic lymph nodes, 0/1 right aortic nodes with tumor involvement. She is considered to have pT1N1aMx, stage IIIC1 endometrial cancer.Â She has been evaluated by [REDACTED] for XRT.Â <br/>
<br/>















<br/>Medical History<br/>

<ul><li>Uterine cancer</li><li>Cancer, female breast, left breast</li></ul>


<br/>


<br/>Surgical History<br/>

<ul><li>[REDACTED], Procedure: Total abdominal hysterectomy with bilateral salpingo-oophorectomy (procedure)</li></ul>


<br/>


<br/>Medications<br/>
Alendronate Oral (Weekly) 70 mg tablet 1 tablet orally every week. administer immed. upon arising with water more than 30 min before food/beverages;stay upright for more than 30 min;do not chew. , Calcium Carbonate Oral 260 mg calcium (648 mg) tablet 500 mg orally 2 times per day. , Amlodipine Oral 5 mg orally daily, Atorvastatin Oral 20 mg orally daily, Letrozole Oral 2.5 mg tablet 1 tablet orally daily. , Ondansetron Oral 8 mg tablet 1 tablet orally every 8 hours as needed for nausea and vomiting. , Aspirin Oral 81 mg capsule 1 capsule orally daily quantity sufficient for 30 days; 2 refills

<br/>


<br/>Adverse Events<br/>
Â Â Â 

<br/>


<br/>Smoking History<br/>


<br/>Smoking Tobacco : Never smoker; Smokeless Tobacco : none found; Vaping : none found

<br/>


<br/>Social History

<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>Alcohol Use: none

<br/>Recreational Drug Use: none

<br/>married female with child<br/>
<br/>

















<br/>Family History<br/>

<ul><li>Father: No History of Disease</li><li>Mother: Cervix cancer</li></ul>


<br/>


<br/>Allergies<br/>
No known medication allergies

<br/>


<br/>Review of Systems

<br/>
<br/>Constitutional: Denies fever, weight loss, fatigue

<br/>Eyes: Denies visual changes

<br/>ENT/Mouth: Denies hearing problems, oral problems

<br/>Cardiovascular: Denies chest pain, palpitations

<br/>Respiratory: Denies shortness of breath, cough

<br/>Breast: Denies pain, masses, discharge

<br/>Gastrointestinal: Denies abdominal pain, nausea, vomiting, constipation, diarrhea

<br/>Genitourinary: Denies burning, pain on urination, blood in urine, incontinence

<br/>Gynecological: Denies vaginal discharge, abnormal vaginal bleeding

<br/>Musculoskeletal: Denies muscle pain, bone pain, joint pain

<br/>Skin: Denies rashes, itchiness, ulcers

<br/>Neurologic: Denies headaches, dizziness, confusion, seizures, weakness or numbnessÂ 

<br/>Psychiatric: Denies depression, anxiety

<br/>Hematologic/Lymphatic:Â Denies other bleeding, bruising, swollen lymph nodes


<br/>


<br/>Physical Examination

<br/>Blood pressure: 124/76, R arm, Regular, Pulse: 86, Temperature: 97 F, Respirations: 18, O2 sat: 97%, Pain Scale: 0, Height: 58 in, Weight: 132 lb, BSA: 1.53, BMI: 27.59 kg/m2

<br/>
General: Â Alert &amp; oriented, no acute distress<br/>
Skin: Normal<br/>
Breast: Â Deferred<br/>
Lungs: Normal breathing and effort.<br/>
Heart: Normal rate.<br/>
Back: Nontender<br/>
Abdomen: Nondistended.<br/>
Genitourinary: Deferred<br/>
Extremities: No clubbing, cyanosis, or edema<br/>


<br/>


<br/>Laboratory<br/>
<br/>

<br/>
<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>


<br/>



<br/>Radiology<br/>
<br/>



<br/>Pathology<br/>
<br/>


<br/>Impression and Recommendations

<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
[REDACTED] female with:<br/>
<br/>
<br/># Endometrial adenocarcinoma,Â pT1N1aMx, Stage IIIC1,Â ER(+ 95%)/PR (+ 70%) HER2 2+ FISH (-)<br/>
<br/>
[REDACTED], endometrial curettage: confirmed Dx of endometrial adenocarcinoma.<br/>
[REDACTED], laparoscopicÂ TAH + BSO, bilateral pelvic and aortic LND and omentectomy: surg path showed endometrial adenocarcinoma, endometroid type, FIGO grade 3, measuring 4 cm, areas suspicious for lymph vascular invasion,Â myometrial invasion present well beyond 50%, 1/1 left pelvic node with tumor involvement with nodal extension with the greatest tumor deposit of 1.6 cm, 0/4 right pelvic nodes, 0/3 left aortic lymph nodes, 0/1 right aortic nodes with tumor involvement.<br/>
[REDACTED] - [REDACTED], concurrent chemoXRT with Cisplatin 40 mg/m2 week x 2<br/>
[REDACTED] - [REDACTED], Carbo + Taxol q3weeks x 4 cycles (Carbo withheld on C1D1)Â <br/>
[REDACTED] - [REDACTED], brachytherapy<br/>
[REDACTED], CT:Â  no evidence of mets to chest, abd and pelvis. ST stranding in the perirectal fat 2/2 XRT or post-tx changes. no residual or recurrent dz.Â 

<br/>


<br/># Lt breast cancer, early stageÂ 

<br/>10/2023, dx'ed by MMG and US breast that showed a small Lt breast mass (the details unknown)

<br/>[REDACTED], Lt mastectomy by [REDACTED] [REDACTED] and path: 1.6 cm DCIS, high grade, cribriform, clear margins, no invasive component identified, no Paget's dz noted.Â 

<br/>requesting ER/PR/Her-2 status on tumor sample on SUN LAB

<br/>11/2023, Lt mastectomy by [REDACTED] [REDACTED].

<br/>[REDACTED], Letrozole 2.5 mg po qd.

<br/>[REDACTED], U/S R breast. BIRADs Cat 3. Probably benign mass noted right breast 2:00 1cm from nipple measuring 13x9x6 mm.<br/>
[REDACTED], R MMG.Â Asymmetry in the medial right breast impression effaces on spot compression views and ultrasound is recommended.<br/>
[REDACTED], U/S R breast. BIRADs Cat 3. Probably benign. Right breast 3:00 hypoechoic lesion. Recommend FU R breast U/SÂ [REDACTED].<br/>


<br/>


<br/># Osteoporosis prophylaxis

<br/>on AI

<br/>on Calcium + Alendronate

<br/>
Clinical status: stableÂ <br/>
CA125: 6 ([REDACTED]) -&gt; 6 ([REDACTED]) -&gt; 7 ([REDACTED]) -&gt; 7 ([REDACTED]) -&gt; 8 ([REDACTED]) -&gt; 7 ([REDACTED]) -&gt; 7 ([REDACTED]) -&gt; 5.3 ([REDACTED]) -&gt; 6 ([REDACTED]) -&gt; 6.0 ([REDACTED]) -&gt; 6 ([REDACTED])

<br/>CA 15-3 4.9 ([REDACTED]) -&gt; 5.9 ([REDACTED]) -&gt; 5.2 ([REDACTED]) -&gt; &lt;5 ([REDACTED])<br/>
CEA 20.2 ([REDACTED]) -&gt; 24.9 ([REDACTED]) -&gt; 32.4 ([REDACTED]) -&gt; 25.5 ([REDACTED]) -&gt; 18.2 ([REDACTED]) -&gt; 7.9 ([REDACTED]) -&gt; 7.2 ([REDACTED]) -&gt; 4.4 ([REDACTED]) -&gt; 2.9 ([REDACTED]) -&gt; 2.6 ([REDACTED]) -&gt; 2.4 ([REDACTED]) -&gt; &lt;2 ([REDACTED])<br/>
<br/>
Management:Â 

<br/>- s/p concurrent chemoradiation with low dose Cisplatin 40 mg/m2 Q3wks<br/>
- s/pÂ brachytherapy ([REDACTED]-[REDACTED])Â <br/>
- s/p Carboplatin AUC5 + Paclitaxel 175 mg/m2 Q3wks x 1st cycle (Carbo withheld due to on brachytherapy) Â <br/>
- s/p Carboplatin AUC5 + Paclitaxel 175 mg/m2 Q3wks (up to 4 cycles)Â 

<br/>
Interval History:

<br/>s/p carbo + Taxol up to 4 cycles<br/>
OV [REDACTED]. Reports no sig. interval changes.<br/>


<br/>
<br/>denies axilla/breastÂ pain, mass, lesion or discharge.

<br/>reports compliantÂ to AI and osteoporosis prophylaxis.<br/>
reports scheduled U/S R breast in [REDACTED].<br/>
denies abd pain, bloating or wt changes. Appetite is fine.<br/>
reviewed labs. unremarkable. cancer markers are stable.<br/>
A1C 6.6 controlled DM.<br/>



<br/>
Plan:

<br/>- continue AI with Letrozole (started in 11/2023).

<br/>- continue osteoporosis prophylaxis.<br/>
- blood work PTA (CBC, CMP, CEA, CA15.3, CA125, LDH).

<br/>- next R MMG in 07/2025.<br/>
- U/S R breast in 01/2025, requested and scheduled.<br/>


<br/>- pull DEXA report. (Done in location at [REDACTED][REDACTED])

<br/>- RTC 3 months for labs and U/S R breasts + DEXA.

<br/>


<br/>Treatment plan reviewed with [REDACTED].

<br/>
All questions and concerns were addressed.Â Â Thank you for the opportunity in allowing me to care for this patient.Â  Please do not hesitate to call with any questions or concerns.Â <br/>
<br/>














<br/>Discussion

<br/>


<br/>
<br/>ECOG: N/A


<br/>Depression: N/A

<br/>
<br/>


<br/>


<br/>Diagnosis<br/>


<br/>
<ul><li>Uterine cancer ( Stage Date: [REDACTED], Stage IIIC (T1, N1, M0)-Pathological<br/>
	Extent of Disease: Adjuvant; Lymph Node Involvement: Lymph nodes; )</li></ul>


<br/>CC<br/>
Â Â Â 

<br/>


<br/>Signature<br/>
<br/>


<br/>Note created by [REDACTED] [REDACTED] To NP, Nurse Practitioner, Hematology/Oncology
<br/>Electronically signed by [REDACTED] MD [REDACTED] 11:31 AM PST 
		        </p>
		      </li><li>
		        Phone - Follow-Up: 
		        <p>
		        		

<br/>
<br/>[REDACTED][REDACTED]<br/>
[REDACTED]

<br/>
<br/>Phone: [REDACTED] Fax: [REDACTED]



<br/>


<br/>Patient Name:Â [REDACTED]

<br/>Date of Birth:Â [REDACTED]

<br/>Medical Record #:Â [REDACTED]

<br/>Attending Physician:Â [REDACTED] (Hematology/Oncology)

<br/>Location:Â [REDACTED]

<br/>Referring Physician:Â [REDACTED], M.D. (Gynecological/Oncology)

<br/>


<br/>Phone - Follow-Up

<br/>Date of Visit:Â [REDACTED]

<br/>


<br/>History of Present Illness

<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
[REDACTED] female with history of HTN, HLD who is newly diagnosed with endometrial adenocarcinoma. She noticed blood in urine starting in 3/2022, however did not seek medical evaluation until 9/2022. She was evaluated by her gynecologist on [REDACTED], underwent endometrial curettage. Endocervical curettage did not reveal any malignancy but the endometrial curettage showed endometrial adenocarcinoma. She subsequently underwent laparoscopicÂ  TAH + BSO, bilateral pelvic and aortic nodal dissection and omentectomy by Dr. [REDACTED] on [REDACTED]. The post-surgical pathology showed endometrial adenocarcinoma, endometroid type, FIGO grade 3, measuring 4 cm, areas suspicious for lymph vascular invasion,Â myometrial invasion present well beyond 50%, 1/1 left pelvic node with tumor involvement with nodal extension with the greatest tumor deposit of 1.6 cm, 0/4 right pelvic nodes, 0/3 left aortic lymph nodes, 0/1 right aortic nodes with tumor involvement. She is considered to have pT1N1aMx, stage IIIC1 endometrial cancer.Â She has been evaluated by [REDACTED] for XRT.Â <br/>
<br/>














<br/>Medical History<br/>

<ul><li>Uterine cancer</li><li>Cancer, female breast, left breast</li></ul>


<br/>


<br/>Surgical History<br/>

<ul><li>[REDACTED], Procedure: Total abdominal hysterectomy with bilateral salpingo-oophorectomy (procedure)</li></ul>


<br/>


<br/>Medications<br/>
Alendronate Oral (Weekly) 70 mg tablet 1 tablet orally every week. administer immed. upon arising with water more than 30 min before food/beverages;stay upright for more than 30 min;do not chew. , Amlodipine Oral 5 mg orally daily, Atorvastatin Oral 20 mg orally daily, Ondansetron Oral 8 mg tablet 1 tablet orally every 8 hours as needed for nausea and vomiting. , Aspirin Oral 81 mg capsule 1 capsule orally daily quantity sufficient for 30 days; 2 refills, Letrozole Oral 2.5 mg tablet 1 tablet orally daily. , Calcium Carbonate Oral 260 mg calcium (648 mg) tablet 500 mg orally 2 times per day. 

<br/>


<br/>Adverse Events<br/>
Â Â Â 

<br/>


<br/>Smoking History<br/>


<br/>Smoking Tobacco : Never smoker; Smokeless Tobacco : none found; Vaping : none found

<br/>


<br/>Social History

<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>Alcohol Use: none

<br/>Recreational Drug Use: none

<br/>married female with child<br/>
<br/>
















<br/>Family History<br/>

<ul><li>Father: No History of Disease</li><li>Mother: Cervix cancer</li></ul>


<br/>


<br/>Allergies<br/>
No known medication allergies

<br/>


<br/>Review of Systems

<br/>
<br/>


<br/>Constitutional:Â Denies fever, weight loss, fatigue

<br/>Eyes:Â Denies visual changes

<br/>ENT/Mouth:Â Denies hearing problems, oral problems

<br/>Cardiovascular:Â Denies chest pain, palpitations

<br/>Respiratory: Denies shortness of breath, cough

<br/>Gastrointestinal: Denies abdominal pain, nausea, vomiting, constipation, diarrhea

<br/>Genitourinary:Â Denies burning, pain on urination, blood in urine, incontinence

<br/>Musculoskeletal: Denies muscle pain, bone pain, joint pain

<br/>Skin:Â Denies rashes, itchiness, ulcers

<br/>Neurologic: Denies headaches, dizziness, confusion, seizures, weakness or numbness

<br/>Psychiatric: Denies depression, anxiety

<br/>Hematologic/Lymphatic:Â Denies other bleeding, bruising, swollen lymph nodes


<br/>


<br/>Laboratory<br/>
<br/>

<br/>
<br/>

<br/>CMP<br/>
([REDACTED]) Glucose mg/dL : 95; BUN mg/dL : 26 (H); Creatinine mg/dL : 0.9; Sodium mmol/L : 139; Potassium mmol/L : 5.1; Chloride mmol/L : 104; Calcium mg/dL : 8.8; Albumin g/dL : 4.4; Total protein g/dL : 7.1; Bilirubin, total mg/dL : 0.2; Bilirubin, direct mg/dL : 0.06; Alkaline phosphatase U/L : 53; AST/SGOT U/L : 14; ALT/SGPT U/L : 11; CO2 content mEq/L : 25

<br/>Tumor Markers<br/>
([REDACTED]) TOI CEA ng/mL : 2.6

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>

<br/>Other<br/>
([REDACTED]) CA 15-3 (ROCHE) : 5.9; CA-125 II, ROCHE : 6; eGFR(MDRD) : 62 (L)


<br/>



<br/>Radiology<br/>
<br/>



<br/>Pathology<br/>
<br/>



<br/>Impression and Recommendations

<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
<br/>
[REDACTED] female with:<br/>
<br/>
<br/># Endometrial adenocarcinoma,Â pT1N1aMx, Stage IIIC1,Â ER(+ 95%)/PR (+ 70%) HER2 2+ FISH (-)<br/>
<br/>
[REDACTED], endometrial curettage: confirmed Dx of endometrial adenocarcinoma.<br/>
[REDACTED], laparoscopicÂ TAH + BSO, bilateral pelvic and aortic LND and omentectomy: surg path showed endometrial adenocarcinoma, endometroid type, FIGO grade 3, measuring 4 cm, areas suspicious for lymph vascular invasion,Â myometrial invasion present well beyond 50%, 1/1 left pelvic node with tumor involvement with nodal extension with the greatest tumor deposit of 1.6 cm, 0/4 right pelvic nodes, 0/3 left aortic lymph nodes, 0/1 right aortic nodes with tumor involvement.<br/>
[REDACTED] - [REDACTED], concurrent chemoXRT with Cisplatin 40 mg/m2 week x 2<br/>
[REDACTED] - [REDACTED], Carbo + Taxol q3weeks x 4 cycles (Carbo withheld on C1D1)Â <br/>
[REDACTED] - [REDACTED], brachytherapy<br/>
[REDACTED], CT:Â  no evidence of mets to chest, abd and pelvis. ST stranding in the perirectal fat 2/2 XRT or post-tx changes. no residual or recurrent dz.Â 

<br/>


<br/># Lt breast cancer, early stageÂ 

<br/>10/2023, dx'ed by MMG and US breast that showed a small Lt breast mass (the details unknown)

<br/>[REDACTED], Lt mastectomy by [REDACTED] [REDACTED] and path: 1.6 cm DCIS, high grade, cribriform, clear margins, no invasive component identified, no Paget's dz noted.Â 

<br/>requesting ER/PR/Her-2 status on tumor sample on SUN LAB

<br/>11/2023, Lt mastectomy by [REDACTED] [REDACTED].

<br/>[REDACTED], Letrozole 2.5 mg po qd.

<br/>[REDACTED], U/S R breast. BIRADs Cat 3. Probably benign mass noted right breast 2:00 1cm from nipple measuring 13x9x6 mm.<br/>
[REDACTED], R MMG.Â Asymmetry in the medial right breast impression effaces on spot compression views and ultrasound is recommended.<br/>
[REDACTED], U/S R breast. BIRADs Cat 3. Probably benign. Right breast 3:00 hypoechoic lesion. Recommend FU R breast U/SÂ [REDACTED].<br/>


<br/>


<br/># Osteoporosis prophylaxis

<br/>on AI

<br/>on Calcium + Alendronate

<br/>
Clinical status: stableÂ <br/>
CA125: 6 ([REDACTED]) -&gt; 6 ([REDACTED]) -&gt; 7 ([REDACTED]) -&gt; 7 ([REDACTED]) -&gt; 8 ([REDACTED]) -&gt; 7 ([REDACTED]) -&gt; 7 ([REDACTED]) -&gt; 5.3 ([REDACTED]) -&gt; 6 ([REDACTED]) -&gt; 6.0 ([REDACTED])

<br/>CA 15-3 4.9 ([REDACTED]) -&gt; 5.9 ([REDACTED]) -&gt; 5.2 ([REDACTED])<br/>
CEA 20.2 ([REDACTED]) -&gt; 24.9 ([REDACTED]) -&gt; 32.4 ([REDACTED]) -&gt; 25.5 ([REDACTED]) -&gt; 18.2 ([REDACTED]) -&gt; 7.9 ([REDACTED]) -&gt; 7.2 ([REDACTED]) -&gt; 4.4 ([REDACTED]) -&gt; 2.9 ([REDACTED]) -&gt; 2.6 ([REDACTED]) -&gt; 2.4 ([REDACTED])<br/>
<br/>
Management:Â 

<br/>- s/p concurrent chemoradiation with low dose Cisplatin 40 mg/m2 Q3wks<br/>
- s/pÂ brachytherapy ([REDACTED]-[REDACTED])Â <br/>
- s/p Carboplatin AUC5 + Paclitaxel 175 mg/m2 Q3wks x 1st cycle (Carbo withheld due to on brachytherapy) Â <br/>
- s/p Carboplatin AUC5 + Paclitaxel 175 mg/m2 Q3wks (up to 4 cycles)Â 

<br/>
Interval History:

<br/>s/p carbo + Taxol up to 4 cycles<br/>
PV [REDACTED]. Reports no sig. interval changes.<br/>


<br/>
<br/>denies R breast pain, mass, lesion or discharge.

<br/>reports compliance to AI and osteoporosis prophylaxis.<br/>
reports have enough supply. reports she is now obtaining Rx from special pharmacy for MediCal.Â <br/>
Pt reports will update pharmacy information to record for future refill.<br/>


<br/>reviewed labs. unremarkable. cancer markers stable.

<br/>reviewed U/S R breast 3:00, 4 cm from nipple, has a 0.4 x 0.5 x 0.6 cm hypoechoic lesion.Â  Will have R U/SÂ in 01/2025.


<br/>
Plan:

<br/>- continue AI with Letrozole (started in 11/2023).

<br/>- continue osteoporosis prophylaxis.<br/>
- blood work PTA (CBC, CMP, CEA, CA15.3, CA125).

<br/>- next R MMG in 07/2025.<br/>
- U/S R breast in 01/2025, requested.<br/>


<br/>- pull DEXA report. (Done in location at [REDACTED][REDACTED])

<br/>- RTC 3 months for labs and U/S R breasts.

<br/>


<br/>Treatment plan reviewed by [REDACTED].

<br/>
All questions and concerns were addressed.Â Â Thank you for the opportunity in allowing me to care for this patient.Â  Please do not hesitate to call with any questions or concerns.Â <br/>
<br/>













<br/>Discussion<br/>
<br/>
<br/>
<br/>
<br/>ECOG: N/A


<br/>Depression: Was screened; Outcome positive: No; Screening Date: [REDACTED]; Screening Tool: Patient Health Questionnaire (PHQ9); Total depression score: 0

<br/>


<br/>
<br/>
<br/>Visit was conducted by [ PHONE ].

<br/>
<br/>


<br/>Patient agreed to visit by Phone and copay if applicable.<br/>
<br/>[ 18Â ] minutes were spent with the patient and more than [ 50% ] of time was spent counselling/coordinating care.




<br/>
<br/>Diagnosis<br/>

<ul><li>Uterine cancer ( Stage Date: [REDACTED], Stage IIIC (T1, N1, M0)-Pathological<br/>
	Extent of Disease: Adjuvant; Lymph Node Involvement: Lymph nodes; )</li></ul>


<br/>CC<br/>
Â Â Â <br/>




<br/>


<br/>Signature<br/>
<br/>


<br/>Note created by [REDACTED] [REDACTED] To NP, Nurse Practitioner, Hematology/Oncology

<br/>Electronically signed by [REDACTED] MD [REDACTED] 02:42 PM PDT 
		        </p>
		      </li></ul>
</div><br/><br/>
</body></html>